Collaborative Agreement, Period from First Commercial Sale

No definition available.

Name:	opk_CollaborativeAgreementPeriodfromFirstCommercialSale
Namespace Prefix:	opk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement. Maximum Milestone Payments

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangement.MaximumMilestonePayments
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Grant Repayment

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementGrantRepayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Maximum Milestone Payments

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementMaximumMilestonePayments
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Milestone Payment

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementMilestonePayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Upfront Payment

+ References

No definition available.

+ Details

Name:	opk_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Estimated milestone payment to be received.

+ References

No definition available.

+ Details

Name:	opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License and Collaboration Agreements Proceeds as Up Front Payment

+ References

No definition available.

+ Details

Name:	opk_LicenseandCollaborationAgreementsProceedsasUpFrontPayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Proceeds From Development And License Agreement, Milestone Payment

+ References

No definition available.

+ Details

Name:	opk_ProceedsFromDevelopmentAndLicenseAgreementMilestonePayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Proceeds From Development And License Agreement, Upfront Payment

+ References

No definition available.

+ Details

Name:	opk_ProceedsFromDevelopmentAndLicenseAgreementUpfrontPayment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=opk_ViforFreseniusMedicalCarePharmaLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=opk_DevelopmentandLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=opk_ExclusiveOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=opk_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=opk_LaunchandSalesbasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=opk_TesaroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=opk_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_RxiPharmaceuticalsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	invest_InvestmentAxis=opk_PharmsynthezMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opk_MilestoneAxis=opk_PhaseTwoInitiationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opk_MilestoneAxis=opk_RegulatoryAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opk_MilestoneAxis=opk_SalesRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Strategic Alliances (Details) - USD ($)		1 Months Ended			3 Months Ended	12 Months Ended			20 Months Ended	36 Months Ended
Strategic Alliances (Details) - USD ($)	Oct. 12, 2017	May 31, 2016	Jan. 31, 2015	Dec. 31, 2010	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2017	Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Initial upfront payment	$ 6,000,000
Milestone revenue recognized					$ 0
Grant repayment						$ 0	$ 0	$ 25,889,000
Ownership percentage					4.00%	4.00%			4.00%	4.00%
Vifor Fresenius Medical Care Pharma Ltd
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized									$ 0
Vifor Fresenius Medical Care Pharma Ltd \| Development and License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from license fees received		$ 50,000,000
Vifor Fresenius Medical Care Pharma Ltd \| Exclusive Option
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments, maximum		555,000,000
Vifor Fresenius Medical Care Pharma Ltd \| Regulatory Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments, maximum		37,000,000
Vifor Fresenius Medical Care Pharma Ltd \| Launch and Sales-based Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments, maximum		$ 195,000,000
TESARO
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments, maximum				$ 85,000,000.0
Milestone payment ranges				30,000,000
Upfront payment under license agreements				$ 6,000,000
Maximum period to receive royalties				12 years
TESARO \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized						$ 10,000,000	$ 0	$ 15,000,000
Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized										$ 0
Milestone payments, maximum			$ 275,000,000
Non-refundable upfront payment			295,000,000			295,000,000
Additional milestone payment to be received			275,000,000
Deferred revenue					$ 143,100,000	143,100,000			143,100,000	143,100,000
RXi Pharmaceuticals Corporation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments											$ 50,000,000
Accrued Expenses \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue					54,300,000	54,300,000			54,300,000	54,300,000
Other Long-term Liabilities \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue					$ 88,800,000	$ 88,800,000			$ 88,800,000	$ 88,800,000
Minimum \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment ranges			20,000,000
Maximum \| Pfizer \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment ranges			$ 90,000,000
Pharmsynthez
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Ownership percentage					9.00%	9.00%			9.00%	9.00%
Phase Two Initiation
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payments	6,000,000
Regulatory And Development
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payments	31,000,000
Sales Revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payments	$ 75,000,000